Engineered T cell therapies
A new paradigm in oncology

October 2014

FORWARD LOOKING STATEMENT

This communication expressly or implicitly contains certain forward-looking statements concerning Cellectis SA and its business.

Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Cellectis SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Cellectis SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Brief introduction to Cellectis





Cellectis in brief

Corporate

- Discovery and development in engineered T cell therapy for oncology
- NYSE Alternext Paris (ALCLS)
- 27.9 M shares outstanding (32.5 fully diluted)
- 73 employees

Technologies

I. Nuclease based genome engineering – TALEN™, meganucleases
II. Multi-chain Chimeric Antigen Receptor based of IgE backbone
III. Manufacturing of off-the-shelve frozen pharmaceutical products

- Over 120 patents granted and 350 patent applications

Products

- 12 programs – one preclinical proof of concept
- Lead product: UCART123 allogeneic T cell for AML
- Phase I planed for 2016

Partnerships

- Series of agreements since inception with recurrent revenues
- Alliance with Servier on UCART19 (Phase I for 2015) + 5 targets in oncology
- Alliance with Pfizer on 15 targets in oncology

Subsidiary

- 1 fully owned subsidiary: Cellectis plant sciences in New Brighton, MN (15 FTE)

Core technology





DNA genome engineering

Cellectis' competitive advantage: rational genome engineering
The innovation: NUCLEASES or DNA scissors!



TALEN™
MNs

4 criteria for therapeutic gene editing technologies:

1. Precision: How close a nucleotide could be targeted in the genome?
2. Efficacy: What will be the percentage of cells with a gene editing?
3. Safety: How little does it cut elsewhere (off target effect)?
4. Vectorization: How well could it be vectorized?

15 years of experience in quality, throughput & innovation

Pioneer and leader in genome engineering: core technology

TALEN™ cut DNA at a unique target site (30 base pairs recognition site)

Induce an opening in DNA to allow sequence insertion, deletion and/or repair



AT A SAFE HARBOR LOCUS FOR GENE COMPLEMENTATION

AT THE GENE LOCUS

GENE SPECIFIC

A new paradigm in the treatment of cancer





Expending the space of immunotherapies



Roll out in liquid and solid tumor indications





Broad CAR T cell pipeline(1)



- CD19+ B cell malignancies
- Acute myeloid leukemia (AML)
- Multiple myeloma (MM)
- Multiple myeloma (MM)

(*) Subject to an exclusive worldwide option agreement with Servier (S2-S6, targets undisclosed)
(**) Target under Pfizer-Cellectis joint research effort

(1) Not including 15 targets in Pfizer alliance

Alliance with Servier

On March the 7th, Cellectis has entered into an alliance with Servier

- ✓ Scope: development of
  - UCART19 in B-cell malignancies
  - 5 other candidates in solid tumors

- ✓ Responsibilities:
  - Cellectis will be responsible for the R&D of certain candidates through the end of clinical phase I.
  - Servier may exercise an exclusive worldwide option for each candidate developed under the agreement.
  - Upon exercising each option, Servier will be responsible for taking over clinical development, registration and commercialization of each product.

- ✓ Financials:
  - Upfront payment of **$10 million**
  - Up to **$140 million for each of the six candidates** potentially developed, spread over various milestones in the development and commercialization phases.
  - In addition, Cellectis will receive **royalties on the sales** of commercialized products.

Alliance with Pfizer

On June the 18th, Cellectis has entered into an alliance with Pfizer

- ✓ Scope: development of CAR-T cell therapies in oncology
  - 15 Pfizer targets
  - 12 Cellectis targets
- ✓ Exclusivity:
  - For 4 years, Cellectis will not enter into another preclinical CAR-T alliance in oncology
  - No exclusivity on each Cellectis product once IND filed
- ✓ Responsibilities:
  - Both companies work together on preclinical research for 15 Pfizer targets and 4 Cellectis targets (the other 8 Cellectis targets are developed outside the alliance).
  - Each company is responsible and has all worldwide rights for clinical development and commercialization of any product directed at its own targets.
  - Pfizer has right of first refusal on the products directed at the 4 Cellectis targets developed in the alliance.
- ✓ Financials:
  - Upfront payment of **$80 million**
  - Up to **$185 million for each product targeting a Pfizer target** potentially developed, spread over various milestones in the development and commercialization phases.
  - In addition, Cellectis will receive **royalties on the sales** of commercialized products.
- ✓ Equity:
  - Pfizer purchased about 10% of Cellectis' capital through newly issued shares at a price of €9.25 per share. Shareholders representing more than 45% of voting rights approved that equity agreement.

Management & Conclusion





Management team & board of directors

MANAGEMENT

- **André Choulika**, Chairman and CEO
- **David Sourdive**, Executive Vice President Corporate Development
- **Mathieu Simon**, Executive Vice President, COO
- **Thierry Moulin**, Chief Financial Officer
- **Philippe Duchateau**, Chief Scientific Officer
- **Philippe Valachs**, Company Secretary

BOARD OF DIRECTORS

- André Choulika Ph.D.
- David Sourdive Ph.D.
- Mathieu Simon M.D.
- Laurent Arthaud
- Annick Schwebig M.D.
- Pierre Bastid
- Alain Godard
- Kaminwest represented by Roger J. Hajjar M.D.

The take home message

Our differentiated approach

I. Nuclease based genome engineering – TALEN™, Mega
II. Multi-chain Chimeric Antigen Receptor – the next CAR
III. Manufacturing of off-the-shelve frozen pharmaceutical products

A pipeline addressing 33 targets in oncology

- 12 targets for Cellectis
- 6 targets for Servier
- 15 targets for Pfizer

Phase I for UCART19 in Q3 2015

A strong balance sheet




Thank you

Cellectis
8 rue de la Croix Jarry
75013 Paris
France

www.cellectis.com

Tel. : +33 (0) 1 81 69 16 00






Cellectis plant sciences

Healthier Food Products

October, 2014

The Green Evolution Company

FORWARD LOOKING STATEMENT

This communication expressly or implicitly contains certain forward-looking statements concerning Cellectis SA and its business.

Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Cellectis SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Cellectis SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Summary



Vision

Becoming a new leader in AgBiotech

A consumer and farmer focused plant company

- Focus: Develop new generation plant products
- Target large crop markets: Wheat, Soybean, Potato, …
- Best in Class: innovative products
- Fast time to market 6-10 years *vs*. 13 years
- Reasonable costs: ~$6m per Trait

The Future of AgBiotech Products!

Breakthrough Technology: Gene Editing

- Plants are modified to create value to consumers
  - No foreign DNA added in final products
  - Products are not different from naturally occurring plants
- Strong IP position
  - Exclusive license from Univ of Minnesota on TALEN™
  - Proprietary transformation technologies
- Fast and cost effective development to market
  - Improved selection of events
  - Fast process development

Nuclease Technology and Applications



Cellectis Plant Sciences - Platform

Step 1: Identification of a gene of interest to be edited & development of a nuclease

Step 2: Transient transformation of plant cells with nucleases

Independent plant transformation methods



Gene is disabled by nuclease

TALEN™, MN

Step 3: Regeneration of plants without any foreign DNA

Plant cell | Callus | Plantlet | Field

Introduction

Mission

Healthier Food for a Better Life

- Develop plants with healthier characteristics
- Meet the needs of a growing population
- Produce food in the context of climate change

Cellectis Plant Sciences Inc. at a Glance

Corporate

- Development of new plant breeds with healthier properties
- Founded in 2010 in Minneapolis, Minnesota USA
- 15 employees

Technologies

- Best in class gene editing technologies – TALEN™, meganucleases, Crispr
- A strong know-how in proprietary plant transformation technologies
- Non-transgenic and non regulated products

Products

- Crops: Soybean, Potato, Wheat, Canola
- Cold Storable Potato, No Trans-Fat Soybean Oil
- Open field trial Soybean Trait started Q2-2014

Partnerships

- Industrial partners: Bayer, Monsanto, Syngenta, Mitsubishi, Pepsico, SES Vanderhave, Limagrain
- Alliances with breeders for a path to market on Elite germplasms
- Research partnership with the University of Minnesota

Executive management team

CEO — Luc Mathis, PhD

VP Business Development at Cellectis
CalTech, Institut Pasteur, CNRS fellow
Board Member of Minnesota Chamber of Commerce

CSO — Pr. Dan Voytas, PhD

CEO and co-founder of Phytodyne and AGT Biotech
Elected Fellow of the American Association for the Advancement of Science
Inventor of TALEN Technology
Professor and Director of Genome Engineering Department at the UMN



COO — Feng Zhang, PhD

Research Director at CPS
Co-inventor of TALEN Technology
Iowa State University, University of Georgia, UMN

Director of Product Development — William Haun, PhD

Business Development Director at CPS
Agronomy and Plant Breeding at the University of Wisconsin-Madison , PhD at UMN

The AgBiotech Market

A Concentrated Market



In 10 years, largest Ag companies acquired over 200 other players leaving an empty space behind

An expensive toll for new players

Revenues of Top AgBiotech Companies

Company	Syngenta	Monsanto	Dow AS	Pioneer	Bayer	Limagrain
Revenue	$14.2b	$13.5b	$6.4b	$6.3b	€8.4b	€1.5b

Midsize AgBiotech players

Small number (n=20) of SMEs (50-150+ employees) in the US: Arcadia, Chromatin, Ceres,…

High product development cost: $136m, 13 years

- Cost of technology: licenses needed + costs to develop commercial product
- Cost of deregulation: $35M

Bar is set very high for startups

Risk/reward is tight for investors

Cost-Effective Trait Development at CPS

"Traditional" GM Trait Development Process

13 Years - $136M



CPS Trait Development Process



6-10 Years

$6M / Trait

CPS Breaks the Entry Barrier

Traditional Agbio Industries

The bar for developing new products is set very high

Investment in new comers is low

CPS

The bar for new products is low
Many products can be developed

Investment opportunity

CPS Products

CPS product pipeline

Product	Initiation	Trait Development	Field Trail	Launch
Soybean				
No Trans Fat (High Oleic)				2020/2021
High Oleic/Low Lineoleic				2022/2023
Nematode Resistance				2022/2023
Herbicide Resistance				2022/2023
Gene Stack				2024/2025
Potato				
Cold Storability				2022/2023
Reduced Browning				2025/2026
Gene Stack				2027/2028
Wheat				
Reduced Gluten	2015			2023/2024
Disease Resistance	2015			2023/2024
Gene Stack				2025/2026
Canola				
Reduced Saturated Oil	2015			2023/2024
New Farmer Trait	2015			2023/2024
Gene Stack				2025/2026

Product # 1: Cold Storable Potatoes

Product opportunity – Potato

- Worldwide Market value: $30b (10% in the US)
- 30-50% to Fries and Chips Markets

Issue to be solved: Storability and Yields

- Storability: 9% wasted (sprouting)
- Browning: 15% wasted (sugars)
- Health impact: Acrylamide – Regulatory threshold

Competition:

- Simplot's potato is a GMO Product
- Market (McDonald's, Lays) wants no GM in fried products

Potatoes storage leads to yield losses

1- Potatoes cannot be stored in the cold

Cold induces potatoes sweetening

Cold induces fried potatoes browning

& Acrylamide production (toxicity)



2- Planted in Spring, harvested at Fall

Processed all year long – Storage needed

Current storage leads to large volume wastes

If storage at 22°C ➡ potato will sprout

If storage temperature drops ➡ sugars content change

If potatoes sugars content changes ➡ chips become toxic

Solution for Cold Storage: Reduce Free Sugars



Glucose and Sucrose accumulate during cold storage
-> Browning and Acrylamide production

Cold-Stored Tuber:



Enzyme: Vacuolar Invertase

Cold Storable Tuber:

<u>Objective</u>: Reduce Glucose and Fructose responsible for Browning & Acrylamide during Frying

Product # 1: Cold Storable Potatoes

CPS Vinv KO displays intended sugar levels to avoid browning and Acrylamide

Ranger Russet Tubers stored 14 days at 4°C (fridge temperature)



Product # 1: Cold Storable Potatoes

VInv KO	Wild Type	Wild Type
		
4°C cold stored (14 days)	4°C cold stored (14 days)	22°C stored (14 days)

1.5mm sliced chips fried at 191°C for 3 minutes

Addressing Acrylamide Issue

Fried products from current potato varieties exceed future regulated levels of Acrylamide



4x Acrylamide reduction in cold-stored Vinv KO line compared to the WT



Product # 2: No Trans Fat Soybean Oil

Product opportunity - Soybean

- Worldwide Soybean Market value: $30b (50% in Americas)
- Issue to be solved: Trans Fat Oils - Cardiovascular issues
- In the US: Trans fat label lead to 25% loss of market share
- United Soybean Board target: 30% No Trans Fat Soybean
- Competition: Pioneer and Monsanto, GMO Product

Product # 2: No Trans Fat Soybean Oil



- No Trans Fat label, Healthier
- Higher Heat stability

Not regulated in the US,
Japan, EU, and NZ

Field Trial of No Trans Fat Soybean

Wild type soybean breed

CPS High Oleic breed

- **The morphology of WT and KO plants are identical.**
- **Identical fatty acid profiles in the leaf tissues of WT and KO plants.**

Conclusion: Becoming a Key Player

- Creation of a deep pipeline of Non Regulated Traits and Products

- Vertical Integration by M&A – Focus on Potato and Wheat
  - Potato Fries and Fresh markets
  - Wheat for Gluten Reduced Food applications

- Partner to accelerate
  - Selected partners for development and commercialisation
    - Potato Chips, Soybean, Canola and Wheat
  - Joint Ventures with Industry Leaders in other Key Crops
    - Corn, Rice, Cotton, Alfalfa, Tomato

CPS take home message

A unique position in the industry: a consumer benefit focused company

I. Nuclease based genome engineering – TALEN™, Mega
II. Proprietary transformation technologies
III. No foreign DNA added, non regulated products

A self owned product pipeline:

- Cold induced sweetening resistant potato
- High oleic soybean
- Gluten reduced wheat
- Healthier oil in Canola

First field trial completed for the high oleic soybean

More self owned products to be developed




Cellectis plant sciences

600 County Road D

New Brighton, MN 55112

info_cps@cellectis.com

www.cellectis-plantsciences.com






Groupe Cellectis : situation et états financiers au 30 juin 2014

FORWARD LOOKING STATEMENT

This communication expressly or implicitly contains certain forward-looking statements concerning Cellectis SA and its business.

Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Cellectis SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Cellectis SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Cellectis : une mutation réussie



L’histoire d’une mutation réussie



Un an pour une transformation radicale

I. Recentrage de l'activité

II. Simplification des structures

III. Forte amélioration du résultat net

- Augmentation significative du CA grâce au Thérapeutique
- Réduction des dépenses
  - Réalisation du plan de restructuration initié en 2013
  - Un bilan apuré et renforcé
  - Mise en place d'un contrôle de gestion rigoureux et efficient

➢ Une trésorerie solide permettant d'avoir une visibilité au-delà de 3 ans

➢ Un actionnariat significativement modifié

Recentrage des activités et simplification des structures

- Recentrage sur le Thérapeutique et les Plantes
  - ✓ Thérapeutique : Cellectis SA et Cellectis Bioresearch (filiale à 75%, activité réduite aux contrats en cours)
  - ✓ Plantes: CPS (filiale à 100% située à New-Brighton, Minnesota)
- Cellectis Therapeutics a été fusionnée avec Cellectis SA, Cellectis AB a été vendue, Ectycell va être fusionnée avec CBR.
- Simplification: les activités sont regroupées sur deux sites : Biopark et New-Brighton
- Possibilité de démarrage d'une activité thérapeutique aux USA

Des revenus en hausse

- Les contrats en cours nous assurent des revenus pour les années à venir
  - ✓ Milestones liés au contrat Servier
  - ✓ Etalement de l'upfront Pfizer sur 4 ans à compter d'août 2014
  - ✓ Refacturation de frais de R&D liés au partenariat avec Pfizer
- Des revenus récurrents supplémentaires liés aux produits des licences
- Les autres produits d'exploitation sont en baisse :
  - ✓ Arrêt progressif des programmes subventionnés

Des dépenses réduites et maîtrisées 1/2

- Des effectifs considérablement réduits: le nombre d'ETP est passé de 244 en mars 2013 à 88 en juin 2014
- Une structure simplifiée générant moins de coûts
- Cellectis (73 pers.) est focalisée sur le développement des 33 CART et CPS (15 pers.) sur les 4 principaux produits de la branche plantes
- Des projets d'innovation concentrés sur les axes de développement
- Pfizer finance les dépenses de R&D liées au développement de ses cibles

Des dépenses réduites et maîtrisées

- Un objectif d'excellence dans l'exécution
  - Planification et suivi permanent des projets
  - Mise en place d'un contrôle de gestion rigoureux et efficient:
    - ✓ Etablissement des budgets et révisions périodiques
    - ✓ Mise en place d'un reporting mensuel détaillé
    - ✓ Suivi des écarts et réaction rapides
  - Déploiement de SAP ByDesign comme support de cette démarche

Une situation de trésorerie très favorable

- Avec aujourd'hui plus de 100 M€ de trésorerie, nous pouvons poursuivre tous les développements planifiés
- Une situation considérablement améliorée depuis fin 2013 grâce à:
  - ✓ L'accord signé avec Servier
  - ✓ Une levée de fonds opérée en mars 2014 pour un montant de 20,5 M€
  - ✓ Le contrat signé avec Pfizer : paiement upfront et augmentation de capital pour un montant total de de 84 M€

Evolution de l'actionnariat

Actionnariat au 31 mars 2014



Actionnariat au 31 août2014



Depuis fin 2013, la part des actionnaires étrangers a beaucoup augmenté

Une transformation radicale en un an

31 mai 2013



31 mars 2014



31 août2014





Etats financiers au 30 juin 2014



Groupe Cellectis : événements marquants du 1er semestre 2014

- ✓ 17 février 2014 : accord de collaboration avec Servier.
- ✓ 24 mars 2014 : réalisation d'une augmentation de capital de 20,5 millions
- ✓ 5 juin 2014 : accords avec Thermo Fisher Scientific
- ✓ 18 juin 2014 : accord avec Pfizer
- ✓ 29 juillet 2014: rachat de la filiale Cellectis AB par la société japonaise Takara Bio Inc.
- ✓ Une perte opérationnelle pour le S1 2014 de -2,1 M€ vs -14,7 M€ au S1 2013
- ✓ Cellectis est dorénavant totalement focalisé sur le thérapeutique et CPS sur les plantes

Compte de résultat consolidé du 1er semestre 2014

K€	30/06/2014	30/06/2013	Delta 2014/2013
Chiffre d'affaires	11 078	1 939	471,3%
Autres produits d'exploitation	2 765	3 169	-12,7%
Produits d'exploitation	**13 843**	**5 108**	**171,0%**
Coût des redevances	(1 407)	(928)	51,5%
Frais de recherche et développement	(7 573)	(8 041)	-5,8%
Frais administratifs et commerciaux	(7 107)	(11 903)	-40,3%
Autres produits opérationnels	141	1 050	-86,6%
Autres charges opérationnelles	0	(1)	-100,0%
Total des charges	*(15 946)*	*(19 823)*	-19,6%
Résultat opérationnel	**(2 104)**	**(14 715)**	**-85,7%**
Produits financiers	161	273	-41,0%
Charges financières	(145)	(102)	42,0%
Résultat financier	**16**	**171**	**-90,6%**
Impôts sur le résultat	0	(1 416)	-100,0%
Résultats des activités poursuivies	**(2 088)**	**(15 960)**	**-86,9%**
Résultats des activités destinées à être cédées	(2 888)	(1 858)	55,4%
Résultat de la période	**(4 976)**	**(17 818)**	**-72,1%**

Augmentation des revenus conjuguée à la maîtrise des charges ➔ résultat en forte hausse

Bilan consolidé au juin 2014

ACTIF (en kE)	30/06/2014	30/06/2013	Delta en %
Ecart d'acquisition	-	1 095	-100,0%
Immobilisations incorporelles	2 778	5 526	-49,7%
Immobilisations corporelles	2 876	3 869	-25,7%
Actif financier	538	1 510	-64,4%
Actifs non courants	**6 192**	**12 001**	**-48,4%**
Stocks	276	367	-24,9%
Créances d'exploitation	12 935	12 018	7,6%
Trésorerie et équivalents de trésorerie	20 214	7 559	167,4%
Actifs destinés à être cédés	3 331	-	
Actifs courants	**36 756**	**19 945**	**84,3%**
TOTAL DE L'ACTIF	**42 948**	**31 946**	**34,4%**

PASSIF (en k€)	30/06/2014	30/06/2013	Delta en %
Capital social	1 254	1 054	19,0%
Primes d'émission	152 693	133 244	14,6%
Réserves	(128 801)	(68 232)	88,8%
Résultat net part du groupe	(4 531)	(61 033)	-92,6%
Capitaux propres attribuables aux propriétaires de la société	**20 616**	**5 032**	**309,7%**
Participation ne donnant pas le contrôle	(666)	(216)	207,9%
Capitaux propres	**19 949**	**4 815**	**314,3%**
Emprunts et dettes financières non courants	2 770	3 375	-17,9%
Provisions pour indemnités de départ à la retraite	467	437	7,0%
Passifs non courants	**3 238**	**3 812**	**-15,1%**
Emprunts et dettes financières courants	1 233	691	78,4%
Dettes d'exploitation	14 691	20 174	-27,2%
Provisions courantes	1 446	2 454	-41,1%
Passifs destinés à être cédés	2 391	-	
Passifs courants	**19 761**	**23 319**	**-15,3%**
TOTAL DU PASSIF	**42 948**	**31 946**	**34,4%**

- Apurement significatif des actifs incorporels
- Renforcement des capitaux propres
- Baisse des dettes d'exploitation

Résultat par secteurs opérationnels pour le 1er semestre 2014

S1 2013 (en K€)	Outils et Services	Plantes	Thérapeutique	Inter-co	Consolidé
Chiffre d'affaires	1 461	223	3 152	(2 897)	1 939
Autres produits d'exploitation	555		2 614		3 169
Produits d'exploitation	**2 015**	**223**	**5 766**	**(2 897)**	**5 108**
Coût des redevances	(131)	(22)	(928)	153	(928)
Charges de recherche et de développement	(2 718)	(443)	(6 015)	1 135	(8 041)
Charges administratives	(3 631)	(402)	(9 478)	1 608	(11 903)
Autre produits opérationnels	67		983		1 050
Résultat opérationnel	**(4 396)**	**(644)**	**(9 673)**	**0**	**(14 715)**

S1 2014 (en K€)	Outils et Services	Plantes	Thérapeutique	Inter-co	Consolidé
Chiffre d'affaires	750	516	11 483	(1 671)	11 078
Autres produits d'exploitation	574		2 191		2 765
Produits d'exploitation	**1 323**	**516**	**13 675**	**(1 671)**	**13 843**
Coût des redevances	(172)	(9)	(1 226)		(1 407)
Charges de recherche et de développement	(1 053)	(1 039)	(5 887)	407	(7 573)
Charges administratives	(1 831)	(396)	(6 144)	1 265	(7 107)
Autre produits opérationnels	46		95		141
Résultat opérationnel	**(1 688)**	**(928)**	**513**	**0**	**(2 104)**

20,8 M€

Charges

16,1 M€

- ✓ Réduction des pertes du pôle Outils et Services
- ✓ Plantes: focalisation sur le développement du portefeuille de produits
- ✓ Thérapeutique: résultat opérationnel proche de l'équilibre:
  - Augmentation du chiffre d'affaires générée par les nouveaux contrats
  - Diminution des coûts

Un retournement réussi

Cellectis est :

- ✓ Une organisation performante
- ✓ Focalisée sur le Thérapeutique et les Plantes
- ✓ Une société qui génère du chiffre d'affaires
- ✓ Concentrée sur l'excellence de l'exécution
- ✓ Et sur un planning et un contrôle et rigoureux
- ✓ Une société avec une trésorerie lui donnant une bonne visibilité sur le moyen terme




Merci pour votre attention